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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.011CD147 (alias emmprin or basigin), an integral plasma membrane glycoprotein and a member of the Ig
superfamily, is widespread in normal tissues, but highly up-regulated in many types of malignant cancer
cells. CD147 is multifunctional, with numerous binding partners. Recent studies suggest that complexes
of CD147 with the hyaluronan receptor CD44 and associated transporters and receptor tyrosine kinases
are enriched in the plasma membrane of cancer stem-like cells. Here, we show that subpopulations of
tumor cell lines constitutively expressing high levels of cell-surface CD147 exhibit cancer stem-like cell
properties; that is, they exhibit much greater invasiveness, anchorage-independent growth, spheroid
formation, and drug resistance in vitro and higher tumorigenicity in vivo than those constitutively
expressing low levels of cell-surface CD147. Primary CD147-rich cell subpopulations derived from mouse
mammary adenocarcinomas also exhibit high levels of invasiveness and spheroid-forming capacity,
whereas CD147-low cells do not. Moreover, localization at the plasma membrane of CD44, the EGF
receptor, the ABCB1 and ABCG2 drug transporters, and the MCT4 monocarboxylate transporter is
elevated in cells constitutively expressing high levels of cell-surface CD147. These results show that
CD147 is associated with assembly of numerous pro-oncogenic proteins in the plasma membrane and
may play a fundamental role in properties characteristic of cancer stem-like cells. (Am J Pathol 2013,
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Langone Medical Center, New York, New York.Numerous studies have demonstrated the presence of highly
malignant and chemoresistant cell subpopulations in many
types of cancers,1e5 as well as in established cell lines.6,7
The nature and origin of these cancer stem-like cells are
still controversial, but there is a growing consensus that
tumors contain varying sized subpopulations of these cells
and that these cells may be largely responsible for tumor
recurrence and possibly metastasis. Although several pro-
tein markers are used to identify these subpopulations, the
functional basis for their role in the distinctive properties of
cancer stem-like cells is still poorly understood.
CD147 (alias emmprin and basigin) is an integral plasma
membrane glycoprotein and member of the Ig superfamily
that is widespread in normal tissues, but highly up-regulated
in remodeling tissues and in many types of cancers.8e11
Emmprin was originally identiﬁed as a factor on the
surface of tumor cells that induces matrix metalloproteinase
production in ﬁbroblasts12,13 and was subsequently shownstigative Pathology.
.to be identical to basigin.14 Here we refer to it by the cluster
of differentiation identiﬁer, CD147. More recent work has
shown that tumor cell CD147 induces matrix metal-
loproteinases in endothelial cells and tumor cells them-
selves, resulting in increased tumor invasiveness and
angiogenesis.15e18 However, CD147 clearly has functions
other than matrix metalloproteinase induction, and most
Dai et allikely acts as a functional binding partner for several plasma
membrane proteins, including monocarboxylate trans-
porters,19e21 CD98,22 drug transporters,23,24 MT1-MMP25
and the hyaluronan receptors CD4426 and LYVE-1,24 thus
inﬂuencing activities characteristic of cancer stem-like cells,
such as cell survival and drug resistance24,27e32 and inva-
sion and metastasis.15,25,33e35
In the present study, we used ﬂow cytometric sorting to
isolate cell subpopulations with different constitutive levels
of cell-surface CD147 from three different types of CD147-
expressing tumor cell lines [human malignant peripheral
nerve sheath tumor (MPNST) cells,36 SKOV3 human
ovarian carcinoma cells37 and MDA MB231 human breast
carcinoma cells20], as well as from primary mouse mammary
tumor cells. Tumor cells constitutively expressing high levels
of cell-surface CD147 (CD147high cells) exhibited much
greater invasiveness, anchorage-independent growth, and
drug resistance in culture and higher tumorigenicity in vivo,
compared with those expressing low levels of cell-surface
CD147 (CD147low cells). Moreover, membrane localization
of CD44, EGFR, the ABC-family drug transporters ABCB1/
P-glycoprotein (Pgp) and ABCG2/breast cancer resistance
protein (BCRP), and the monocarboxylate transporter MCT4
was higher in CD147high cells than in CD147low cells.
Materials and Methods
Animals
The FVB/NTg(MMTV-PyVT)634Mul transgenic mice were
obtained from Dennis Watson (Medical University of South
Carolina) and NOD/SCID mice were obtained from The
Jackson Laboratory (Bar Hatbor, ME). Animal housing and
all experimental procedures were conducted in facilities for
laboratory animals provided by the Division of Laboratory
Animal Resources and the studies were approved by the
Institutional Animal Care and Use Committee of Medical
University of South Carolina.
Reagents
Fetal bovine serum was purchased from Atlanta Biologicals
(Lawrenceville, GA), and RPMI 1640, Dulbecco’s modiﬁed
Eagle’s medium, and Ham’s F12 media were purchased from
Sigma-Aldrich. The following antibodies were obtained for
these studies: BCRP/ABCG2 clone BXP-21 (Kamiya
Biomedical, Seattle, WA); Alexa Fluor 647-conjugated
CD44/HCAM (SC-7297), CD44/HCAM (DF1485), MCT4
(H-90) (Santa Cruz Biotechnology, Santa Cruz, CA); Pgp/
ABCB1 (Calbiochem C219; EMD Millipore, La Jolla CA);
mouse anti-humanCD147 (HIM6; BDBiosciences, San Jose,
CA); EGFR (2232; Cell Signaling Technology, Danvers,
MA); b-actin clone AC-15 (Sigma-Aldrich), Alexa Fluor
647-tagged chicken anti-mouse IgG, Alexa Fluor 647-tagged
chicken anti-rabbit IgG, Alexa Fluor 555-tagged goat anti-
mouse IgG, Alexa Fluor 555-tagged goat anti-rabbit IgG578(Invitrogen; Life Technologies, Carlsbad, CA); and goat anti-
mouse horseradish peroxidase and goat anti-rabbit horse-
radish peroxidase (Chemicon; EMD Millipore, Temecula,
CA). Fluorescence-activated cell sorting (FACS) was per-
formed using ﬂuorescein isothiocyanate mouse anti-human
CD147 (HIM6), rat anti-mouse CD147 (AbD Serotec,
Raleigh, NC), chicken anti-rat IgG-Alexa Fluor 488 (Invi-
trogen), and ﬂuorescein isothiocyanate mouse IgG1k isotype
control (BD Biosciences). Pierce Western blotting detection
reagent (enhanced chemiluminescence) was purchased from
Thermo Fisher Scientiﬁc (Rockford, IL). All other chemicals
were of reagent or higher grade.
Cell Culture
SKOV3 human ovarian adenocarcinoma and MDA MB231
human breast carcinoma cell lines were obtained from
ATCC (Manassas, VA). The ST88-14 MPNST cell line was
obtained from Larry Sherman (Oregon Health and Science
University, Portland, OR). The carcinoma and MPNST cells
were maintained in RPMI 1640 and in Dulbecco’s modiﬁed
Eagle’s medium-Ham’s F12 medium, respectively, with
2.38 g/L HEPES, 2 g/L sodium bicarbonate, and 10% fetal
bovine serum, pH 7.4, at 37C in a humidiﬁed incubator
with 5% CO2-enriched air.
Primary mouse mammary carcinoma cells (MMTV-PyMT
cells) were isolated from adenocarcinomas that grow sponta-
neously in FVB/NTg(MMTV-PyVT)634Mul female trans-
genic mice. The tumors were harvested after reaching 0.5 cm
diameter (8- to 11-week-old mice), washed with 2% fetal
bovine serum in PBS, and minced with razor blades. Tissue
was shaken at low speed for 6 hours at 37C in a solution
containing 1 part 10 collagenase/hyaluronidase (Stemcell
Technologies, Vancouver, BC, Canada), 9 parts complete
mouse EpiCult B medium (Stemcell Technologies), 5% fetal
bovine serum, and antibiotic-antimycotic solution (HyClone
Laboratories; Thermo Scientiﬁc, South Logan, UT). Dissoci-
ated tissue was vortexed, centrifuged at 450 g for 5 minutes,
treated with ammonium chloride in Hank’s balanced salt
solution to remove the red blood cells, and then treated with
0.25% trypsin-EDTA (HyClone Laboratories), followed by
5 mg/mL dispase (Stemcell Technologies) and 200 U/mL
DNase I (Stemcell Technologies) in Hank’s balanced salt
solution. The cell suspension was ﬁltered through a 40-mm
nylon mesh before plating in complete mouse EpiCult B
medium supplemented with 5% fetal bovine serum, 4 mg/mL
heparin (Sigma-Aldrich, St. Louis, MO), 10 ng/mL recombi-
nant human basic ﬁbroblast growth factor (rhFGF-basic;
PeproTech, Rocky Hill, NJ), 10 ng/mL recombinant human
epidermal growth factor (rhEGF; PeproTech), and antibiotic-
antimycotic solution. Incubation at 37C for 1 hour in
a humidiﬁed incubator with 5% CO2-enriched air was per-
formed to allow the attachment of stromal cells (mainly
macrophages and ﬁbroblasts) to the plate. Nonadherent cells
were collected and replated overnight in the same medium,
afterwhich themediumwas replacedwith serum-freemedium.ajp.amjpathol.org - The American Journal of Pathology
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Cells were trypsinized into a single-cell suspension using
0.25% trypsin-EDTA (HyClone Laboratories), counted,
blocked with 3% bovine serum albumin in PBS, and treated
with antibodies in culture medium. SKOV3, MDA MB231,
and MPNST cells were incubated with antieCD147-
ﬂuorescein isothiocyanate, or with IgG-ﬂuorescein iso-
thiocyanate as a negative control, for 30 minutes on ice.
Mouse MMTV-PyMT cells were incubated with rat anti-
mouse CD147 (1:50 dilution) for 1 hour, followed by
incubation in chicken anti-rat IgG-Alexa Fluor 488 (1:200)
for 30 minutes. Unbound antibody was washed off, and
cells were then suspended in medium containing 1:1000
propidium iodide, ﬁltered, and sorted on a FACSAria II
system (BD Biosciences). Cells expressing the highest
levels of cell-surface CD147 (the top 10% of SKOV3, MDA
MB231, and MMTV-PyMT cells and the top 20% of
MPNST cells) were selected as the CD147high fraction.
Conversely, those cells expressing the lowest levels of cell-
surface CD147 (the bottom 10% of SKOV3, MDA MB231,
and MMTV-PyMT cells and the bottom 20% of MPNST
cells) were selected as the CD147low fraction.
Recombinant Adenovirus Infections
Recombinant human CD147 adenovirus and control b-
galactosidase (b-gal) adenovirus were constructed and used
as described previously.38,39 CD147 adenovirus dose was
adjusted to cause moderate (two- to ﬁvefold) increases in
expression.
Matrigel Invasion Assay
Matrigel invasion chambers (BD Biosciences) were hydrated
for 2 hours at 37C in culture medium. After hydration, the
medium in the bottom of the well was replaced with fresh
culture medium, and 5  104 cells were plated in the top
chamber. After 24 hours of incubation, the cells were ﬁxed
with 3% paraformaldehyde for 15 minutes at room tempera-
ture; the chambers were then rinsed in PBS and stained with
0.2% crystal violet for 10 minutes. After the chambers had
been washed ﬁve times with water, the cells at the top of the
Matrigel membrane were removed with cotton swabs. The
invaded cells on the bottom side of the membrane were
subsequently counted under a phase-contrast microscope
(DFC320; Leica Microsystems, Wetzlar, Germany).
Anchorage-Independent Growth of Colonies in Soft
Agar
Six-well plates were prepared with a layer of 0.5% agar in
culture medium. Cells (2500 per well) were suspended in
0.35% agarose in culture medium and layered on top of the
0.5% agar. Additional culture medium was added to the top
layer of soft agar twice a week. After 28 days, colonies wereThe American Journal of Pathology - ajp.amjpathol.orgstained with 0.005% crystal violet and photographed under
a phase-contrast microscope (Leica DFC320).
Spheroid Formation
Cells were plated in ultralow attachment plates at a density
of 20,000 cells/mL and were cultured in complete Mam-
moCult medium (Stemcell Technologies) supplemented
with 0.5 mg/mL hydrocortisone and 4 mg/mL heparin. Cells
were incubated at 37C and in 5% C02-enriched air for 7 to
12 days, with the medium being changed every 3 or 4 days.
Cell were then photographed under a phase-contrast mi-
croscope (Leica DFC320).
Drug Resistance Assay
Cells were seeded in 96-well plates and incubated for
approximately 48 hours before the experiment to reach
a ﬁnal density of approximately 70% conﬂuency. Cells were
then treated with doxorubicin (0, 0.001, 0.01, 0.1, 1, 10,
100, or 1000 mmol/L) for 96 hours at 37C in an incubator
with 5% CO2-enriched air. After three washes with PBS,
adherent cells were trypsinized and counted in a Z1 particle
counter (Beckman Coulter; Fullerton, CA).
FURA-2 AM Assay
Efﬂux of Fura-2-acetoxymethyl ester (FURA-2 AM) was
measured as described previously.40 Cells were incubated in
96-well plates to reach a ﬁnal density of approximately 70%
conﬂuency. Cells were treated in feed medium containing
2.5 mmol/L FURA-2 AM. After 1 hour of incubation, plates
were read (excitation 340 nm, emission 500 nm) from the
bottom in an FLx800 microplate ﬂuorescence reader (Bio-
Tek Instruments, Winooski, VT) to determine FURA-2 AM
levels in the cell layer.
Immunoblot Analysis
Whole-cell lysates were prepared for immunoblotting using
a radioimmunoprecipitation assay buffer modiﬁed to contain
1 mmol/L phenylmethylsulfonyl ﬂuoride, 10 mg/mL apro-
tinin and leupeptin, 2 mmol/L sodium orthovanadate, and
10 mmol/L sodium ﬂuoride. Protein content was determined
by BCA assay (Pierce; Thermo Fisher Scientiﬁc, Rockford,
IL), and aliquots containing 25 to 50 mg of protein were
solubilized in SDS sample buffer, resolved on Pierce 4% to
20% reducing polyacrylamide gels (Thermo Fisher Scien-
tiﬁc), transferred to nitrocellulose (GE Osmonics-Micron
Separations, Westborough, MA), and stained with antibody.
Flow Cytometry Analyses
Cells (1  105) were trypsinized to achieve single-cell
suspensions, counted, blocked with 3% bovine serum
albumin in PBS, and incubated with antibody for 30 minutes579
Figure 1 Flow sorting of CD147low and CD147high subpopulations from
MPNST cells and SKOV3 ovarian carcinoma cells. MPNST cells (A) and SKOV3
cells (B) were sorted with FACS for CD147. Those cells expressing the highest
levels of cell-surface CD147 (the top 10% of SKOV3 cells and 20% of MPNST
cells) were selected as the CD147high fraction. Conversely, those cells
expressing the lowest levels of cell-surface CD147 (the bottom 10% of SKOV3
cells and 20% of MPNST cells) were selected as the CD147low fraction. Sorting
of MDA MB231 cells was performed in a similar fashion as the SKOV3 cells
(data not shown). Western blot analysis was performed of whole-cell lysates
of CD147low and CD147high fractions fromMPNST cells (25 mg protein) (A) and
SKOV cells (50 mg protein) (B). Only the CD147 band is shown (A and B, upper
right corner), at approximately 55kDa; a faint band at approximately 35 kDa
was also present in each case (not shown).
Figure 2 Increased invasiveness of CD147high versus CD147low cells.
CD147 ﬂow-sorted subpopulations of MPNST (A) or SKOV3 (B) cells were
plated on Matrigel-coated invasion chambers and analyzed. C: CD147high
and CD147low subpopulations of SKOV3 cells were compared with CD147low
cells infected with CD147 or b-gal adenovirus. Data are expressed as means
of three or more independent experiments. *P < 0.05 between CD147
subpopulations. Micrographs are representative of three or more inde-
pendent experiments. Original magniﬁcation, 50.
Dai et alon ice. Unbound antibody was removed by subsequent
washes, and cells were analyzed no later than 1 hour after
staining on a FACSCalibur system (BD Biosciences).
Xenografts
After trypsinization and a PBS wash, FACS-sorted SKOV3
cells were suspended in a 1:4 ratio of PBS to Matrigel (0.2
mL), and then 104 to 105 CD147low or 103 to 104 CD147high
cells were injected subcutaneously into the ﬂank of NOD/
SCID mice with a 23-gauge needle. Tumors were excised
and weighed after 12 weeks.
Results
CD147high Tumor Cell Subpopulations Exhibit Elevated
Invasiveness, Anchorage-Independent Growth,
Spheroid Formation, and Drug Resistance Compared
with CD147low Subpopulations
CD147high and CD147low subpopulations were prepared by
FACS from ST88-14 human MPNST cells and SKOV3
human ovarian carcinoma cells as described in Materials
and Methods. Results from ﬂow cytometry analyses of
CD147 distribution and Western blot analyses of the levels
of total CD147 in the CD147high and CD147low subpopu-
lations are shown in Figure 1. The CD147high cells typically
expressed more CD147 than the CD147low cells (Figure 1);
however, in some preparations the difference in total
expression was insigniﬁcant, despite a clear-cut difference
in the level of cell-surface CD147. Very similar subpopu-
lations of cells were obtained from MDA MB231 human
mammary carcinoma cells (data not shown).580We used a Transwell Matrigel invasion assay (BD
Biosciences) to determine the constitutive differences in
invasiveness of the CD147high and CD147low subpopula-
tions. The CD147high subfractions of both MPNST and
SKOV3 cells were highly invasive, but their CD147low
counterparts were not (Figure 2, A and B). Virtually iden-
tical results were obtained for MDA MB231 cells (data not
shown). To conﬁrm that differences in invasiveness were
directly related to expression of cell-surface CD147, we
infected the CD147low subfraction of SKOV3 cells with an
adenovirus driving expression of CD147. This led to
a dramatic increase in invasion, to a level similar to that of
the CD147high subfraction (Figure 2C).
We also tested the CD147high and CD147low subpopula-
tions of MPNST and SKOV3 cells for their ability to grow as
colonies in soft agar, ameasure of the ability of cells to grow in
an anchorage-independent manner, which is characteristic of
transformed cells.41 Strikingly, the CD147low subpopulations
of both cell types repeatedly failed to grow colonies, whereas
the CD147high subpopulation of both cell lines demonstrated
a strong constitutive ability to form colonies in soft agar
(Figure 3A). The ability to form spheroids under nonadhe-
sive culture conditions is a common feature of cancer stem-
like cells isolated from carcinoma cell lines or primaryajp.amjpathol.org - The American Journal of Pathology
Figure 3 Increased anchorage-independent growth and spheroid
formation in CD147high versus CD147low cells. A: CD147 ﬂow-sorted subpop-
ulations of MPNST or SKOV3 cells were cultured in soft agar for analysis of
colony formation. B: CD147 ﬂow-sorted subpopulations of MDA MB231 or
SKOV3 cells were cultured in nonadhesive wells for analysis of spheroid
formation. Colonies (A) or spheroids (B) formed from CD147high but not
CD147low subpopulations of cells. C: Proliferation under routine anchorage-
dependent cell culture conditions was also compared over a 96-hour period,
but no signiﬁcant differences were observed. Original magniﬁcation, 10.
Figure 4 Increased drug resistance and ABC transporter activity in
CD147high versus CD147low cells. A and B: Cell survival after treatment with
doxorubicin (Dox) (left panels) and FURA-2 AM efﬂux (right panels) was
analyzed with CD147 ﬂow-sorted subpopulations of MPNST (A) and SKOV3
(B) cells. C: Unsorted control, uninfected SKOV3 cells were infected with
CD147 or b-gal adenovirus. Data are expressed as means  SEM of triplicate
wells. Cell survival results are representative of three or more independent
experiments; FURA-2 AM efﬂux results are representative of four or more
independent experiments. *P < 0.05 between CD147 subpopulations (A
and B) or between b-gal and CD147 adenovirus-infected SKOV3 cells (C).
CD147-Dependent Tumor Cell Heterogeneitycarcinomas.6,7,42,43 We therefore tested the ability of
CD147high and CD147low subpopulations of SKOV3
ovarian and MDA MB231 breast carcinoma cells to form
spheroids and found that the CD147high cells readily form
spheroids, whereas CD147low cells do not (Figure 3B). We
also examined cell proliferation under routine cell culture
conditions; however, despite the differences in anchorage-
independent proliferation observed (Figure 3, A and B),
we found no signiﬁcant differences in anchorage-dependent
proliferation between CD147high and CD147low subpopu-
lations for SKOV3 ovarian carcinoma or MPNST cells
(Figure 3C). This is in accord with previous results showing
that experimental elevation of CD147 expression leads to
increased anchorage-independent but not anchorage-
dependent growth.32
We thenmeasured the effects of doxorubicin on cell survival
of the CD147high and CD147low subpopulations prepared from
MPNST and SKOV3 cells. The CD147high subpopulations
were approximately 100 to 1000 times more resistant to
doxorubicin than the corresponding CD147low subpopulations
(Figure 4, A and B). The approximate half-maximal inhibitory
concentration (IC50) values obtained in this series of experi-
ments were 10 mmol/L for the MPNST-CD147high cells,
compared with 0.01 mmol/L for the MPNST-CD147low cells,
and 5 mmol/L for the SKOV3-CD147high cells, compared with
0.05 mmol/L for the SKOV3-CD147low cells.
Drug resistance is often due to enhanced drug export by
ATP-dependent efﬂux pumps such as Pgp. We therefore
measured the levels of efﬂux of FURA-2 AM, a ﬂuorescentThe American Journal of Pathology - ajp.amjpathol.orgsubstrate for Pgp. In cells expressing high levels of Pgp,
intact FURA-2 AM is rapidly transported out of the cell,
whereas in the absence of transporter activity it is cleaved to
FURA 2 and accumulates in the cytosol. Thus, transporter
activity is inversely proportional to accumulation of cyto-
solic FURA 2 ﬂuorescence.40 Consistent with our data on
doxorubicin resistance, the CD147high subpopulation from
both cell types exhibited increased efﬂux, compared with
the CD147low subpopulations (Figure 4, A and B). To show
that differences in drug resistance were directly inﬂuenced
by CD147 levels, we also compared SKOV3 cells infected
with adenovirus driving expression of CD147 with SKOV3
cells infected with control b-gal adenovirus. Increased
CD147 caused the cells to be at least 1000 times more
resistant to doxorubicin than the controls (Figure 4C) and to
efﬂux higher amounts of FURA 2 (Figure 4C).581
Figure 5 Increased invasiveness and spheroid formation in primary
CD147high versus CD147low cells from MMTV-PyMT mouse mammary tumors.
A: Tumor cells were isolated from MMTV-PyMT adenocarcinomas and sorted
with FACS for CD147. The top 10% of cells expressing the highest levels of
cell-surface CD147 were selected as the CD147high fraction and the bottom
10% were selected as the CD147low fraction. Western blot analysis of whole-
cell lysates of CD147low and CD147high fractions is shown in the upper right
corner. B and C: CD147 ﬂow-sorted subpopulations were plated on
Matrigel-coated chambers for analysis of invasiveness (B) and were
cultured in nonadhesive wells for analysis of spheroid formation (C).
Original magniﬁcation, 10. *P < 0.05.
Dai et alPrimary CD147high Cell Subpopulations from MMTV-
PyMT Mouse Mammary Carcinomas Exhibit Elevated
Invasiveness and Spheroid Formation
To determine whether the differences in properties of
CD147high and CD147low subpopulations described above
were restricted to cell lines, we separated these subpopula-
tions from primary mouse tumor cells isolated from
MMTV-PyMT mouse tumors (Figure 5A). Mouse CD147 is
typically more heterogeneous in size than human CD147.39
In a similar manner to the cell lines, primary CD147high cells
from these tumors were much more invasive than the cor-
responding CD147low cells (Figure 5B). Furthermore, the
primary CD147high cells readily formed spheroids under
nonadhesive culture conditions, whereas CD147low cells did
not (Figure 5C).Figure 6 Increased membrane localization of CD44, EGFR, and trans-
porters in CD147high versus CD147low cells. CD147 ﬂow-sorted subpopula-
tions of MPNST (A) and SKOV3 (B) cells were analyzed by ﬂow cytometry for
membrane localization of CD44, Pgp, BCRP, EGFR, and MCT4.CD147high Cells Have Elevated Levels of Membrane-
Localized CD44, EGFR, and Transporters
Previous studies from this and other laboratories have shown
that hyaluronan-CD44 interactions promote formation of
signaling complexes containing receptor tyrosine kinases
(RTKs) and transporters in the plasma membrane of cancer
cells44,45 and that CD147 is associated with these com-
plexes.26,31,46 We therefore examined the levels of RTK,
EGFR, and the transporters Pgp, BCRP, and MCT4 at the582surface of CD147high and CD147low subpopulations from
MPNST and SKOV3 cells by FACS analysis. The CD147high
subpopulations expressed higher levels of CD44, EGFR,
Pgp, BCRP, and MCT4 in their membranes than did
the CD147low subpopulations (Figure 6). Furthermore,
CD147high cells produced higher amounts of hyaluronan, the
major ligand for CD44 (data not shown). However, Western
blot analyses did not show consistent differences in total
levels of expression of CD44, EGFR, Pgp, BCRP, or MCT4
(data not shown). Thus, cells with relatively high levels of
cell-surface CD147 exhibit correspondingly high levels of
these other proteins at the cell surface.ajp.amjpathol.org - The American Journal of Pathology
CD147-Dependent Tumor Cell HeterogeneityCD147high Tumor Cell Subpopulations Are More
Tumorigenic than CD147low Subpopulations
Finally, we compared the capacity of constitutively
CD147high and CD147low subpopulations of cells to form
tumors in vivo. The relative weights of tumors formed by
CD147high and CD147low subpopulations of SKOV3 cells
grown as xenografts in NOD/SCID mice are shown in
Figure 7. Signiﬁcantly larger tumors were formed by the
CD147high cells than the CD147low cells after injection of
equivalent cell numbers (104 cells per mouse) (Figure 7).
Injection of 10 times lower numbers of CD147high cells (103
cells per mouse) resulted in variably sized tumors of higher
average size than those formed from 104 CD147low cells;
injection of higher numbers of CD147low cells (105 cells per
mouse) produced smaller tumors than either 103 or 104
CD147high cells (data not shown). In these cases, however,
the differences were not statistically signiﬁcant.
Discussion
Previous studies from our laboratory and those of other
investigators have demonstrated that experimental manipu-
lation of CD147 levels inﬂuences tumor cell invasive-
ness,17,25 anchorage-independent growth and anoikis,32,47
drug resistance,24,27 lactate transport,20,26 and tumor
progression.15,33,34
In the present study, we examined the properties of cell
subpopulations, with different constitutive levels of cell-
surface CD147, that were derived directly from malignant
human cell lines or primary mouse tumor cells. Subpopula-
tions of cells that exhibit constitutively high levels of
cell-surface CD147 were found to be highly invasive,
anchorage-independent, drug resistant, spheroid-forming,
and tumorigenic, whereas cells that exhibit constitutively
low levels of cell-surface CD147 were found to be nonin-
vasive, anchorage-dependent, drug sensitive, non-spheroid-
forming, and less tumorigenic. Our ﬂow cytometry results
(Figures 1 and 5A) indicate that each of the cell types used inFigure 7 CD147high SKOV3 cells (CD147-lo) are more tumorigenic than
CD147low cells (CD147-hi) in vivo. CD147high and CD147low subpopulations
were isolated from SKOV3 human ovarian carcinoma cells by ﬂow sorting
and were injected into the ﬂanks of NOD/SCID mice (104 cells per mouse).
Mice were sacriﬁced after 12 weeks and tumor weight was measured. Data
are expressed as means  SEM. n Z 5 mice per group. *P < 0.05.
The American Journal of Pathology - ajp.amjpathol.orgthe present study exhibits a continuum of cell-surface CD147
expression, rather than a bimodal distribution. Thus, our
selection of CD147high and CD147low cells is arbitrary, and it
is to be expected that subpopulations of cells with interme-
diate properties would also be present. Likewise, it is
unknown whether CD147high and CD147low cells arise
stochastically or represent hierarchical cell subpopulations.
It is striking that these dramatic differences in cellular
properties correspond with different levels of cell-surface
CD147, but not necessarily with different levels of total
CD147, because differences in the total expression of CD147
in CD147high versus CD147low cells were often small or
insigniﬁcant. These observations suggest that there are
considerable differences in transit of CD147 to or from the
cell surface in these two subpopulations. A previous study of
trafﬁcking of CD147 and MCT4 to the cell surface showed
that the levels of cell-surface CD147 and MCT4 were
mutually dependent on their interaction with one another.20
Because the CD147high cells studied here also exhibited
higher levels of cell-surface MCT4, it is possible that similar
effects on trafﬁcking occurred in these cells. Interestingly,
CD44, EGFR, Pgp, and BCRP were also higher in the
membranes of CD147high cells than CD147low cells. In
previous studies, we had shown that CD147 associates with
CD44, Pgp, and BCRP at the cell surface,24,26,46 but it is not
known whether CD147 is directly responsible for trafﬁcking
of these proteins to the cell surface. It is likely, however, that
the increased levels of these proteins at the surface of
CD147high cells are at least in part responsible for their more
malignant properties.
CD147 has been associated with tumor progression and
invasiveness ever since its discovery as a matrix
metalloproteinase-inducing factor.15e17,33,34,48e53 In accord
with these previous studies, we show here that subpopula-
tions of cells expressing high constitutive levels of CD147
are much more invasive than those with low levels of
CD147 expression. Recently, we have also shown that
experimental overexpression of CD147 to a relatively
moderate degree is sufﬁcient to induce invasiveness and
formation of active invadopodia in the phenotypically
normal breast epithelial cell line MCF-10A, and that down-
regulation or up-regulation of CD147 in the metastatic
breast carcinoma cell line MDA MB231 correspondingly
alters invasiveness and active invadopodia formation.25 In
that study, we showed that CD147 induces the expression of
MT1-MMP and is present in close association with MT1-
MMP in lipid raft-like domains.25 In a more recent study,
we demonstrated that CD147 is also associated with EGFR
and CD44 in similar lipid domains and that CD147 induces
invasiveness via up-regulation of EGFR-Ras-ERK and
hyaluronan-CD44 signaling as well as MT1-MMP expres-
sion (Grass et al, unpublished data). We have also shown
that increased CD147 induces formation of ErbB2-
containing complexes within lipid microdomains, accom-
panied by increased ErbB2 activation.54 These results
indicate that CD147 plays a fundamental role in the583
Dai et alsignaling pathways leading to tumor cell malignancy. Two
major questions remain unanswered. First, how does CD147
induce formation of these complexes? Second, does CD147
inﬂuence the fundamental organization of plasma membrane
proteins (eg, into lipid microdomains) or promote protein
trafﬁcking and complex formation (thereby in turn inﬂu-
encing membrane organization)?
Recently, we observed enrichment of CD147-containing
complexes, similar to those described above, in primary
cancer stem-like cells isolated from ascites ﬂuid from ovarian
carcinoma patients,46 suggesting that the properties of these
highly aggressive, therapy-resistant subpopulations of cancer
cells may be linked to formation of such complexes. Our
results here, showing that CD147high cells are much more
tumorigenic than CD147low cells, also suggest a relationship
between CD147-containing complexes and cancer stem-like
cells. Likewise, we have demonstrated that CD147high cells
are much more drug-resistant than CD147low cells and more
readily form spheroids, properties that are also characteristic
of cancer stem-like cells.2,4
Another striking observation is the relationship between
the activities of CD147 and CD44, a major marker for
cancer stem-like cells.55 Several studies have demonstrated
close association of CD147 and CD44.26,31,46 We have
shown that up-regulation of CD147 induces synthesis of
hyaluronan,32 the major ligand for CD44, as well as several
downstream effects of hyaluronan-CD44 signaling, in-
cluding anchorage-independent growth,32 lactate trans-
port,26 invasiveness (Grass et al, unpublished data), and
ErbB2 signaling.54 In previous studies, we have demon-
strated the involvement of cell-surface complexes contain-
ing CD44 and RTKs or transporters. Moreover, we have
shown that antagonists of these interactions with CD44
inhibit growth of tumors initiated by cancer stem-like
cells.46,56 The data reported here indicate that CD147, as
well as CD44,45,55 is an important target for treatment of
aggressive, therapy-resistant cancers, and in particular their
cancer stem-like subpopulations.Acknowledgments
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